Clinical behavior of patients with asthma during the COVID-19 pandemic
Allergy: European Journal of Allergy and Clinical Immunology
; 76(SUPPL 110):449-450, 2021.
Article
in English
| EMBASE | ID: covidwho-1570373
ABSTRACT
Background:
Asthma is a chronic respiratory disease, and respiratory viruses are well-known triggers for asthma exacerbations. The novel coronavirus named SARS-CoV-2, which causes COVID-19, can present with pulmonary symptoms. Several studies suggest that IL-13, an allergic asthma mediator, should prevent asthma exacerbations by SARS-CoV-2. The objective of this study was to evaluate the clinical behavior of patients with asthma during the COVID-19 pandemic. Asthma is a chronic respiratory disease, and respiratory viruses are well-known triggers for asthma exacerbations.The novel coronavirus named SARS-CoV-2, which causes COVID-19, can present with pulmonary symptoms.Several studies suggest that IL-13, an allergic asthma mediator, should prevent asthma exacerbations by SARS-CoV-2. The objective of this study was to evaluate the clinical behavior of patients with asthma during the COVID-19 pandemic.Method:
This was a retrospective study of electronic medical records of adult asthmatic patients, being followed up in a tertiary service and who received telephone calls for rescheduling the face-to-face consultations, during the COVID-19 pandemic period.Demographic data, asthma symptoms, frequency of atopy, presence of comorbidities and symptoms related to coronavirus infection were analyzed. Patients were classified according to their history of asthma attacks.Results:
Two hundred and seven patients were included, and of them, 165 patients (79.7%) were female, with a mean age of 53.3 years and asthma duration of 35 years. Atopy was confirmed in 156 patients (81.7%). The main comorbidities were obesity (32.9%), high blood pressure (47.3%), diabetes mellitus (17.4%) and emotional stress (68.1%). Of the total, 87 patients (42%) had acute symptoms, of which 20 (9.7%) sought emergency care and 15 of 20 patients (75%) were investigated for Covid-19, all of which were negative. Of the total, only 7 patients (3.4%) exacerbated and required systemic corticosteroids. During this study, the more frequent complaints among asthmatic patients with acute respiratory symptoms were dyspnea, cough, asthenia and headache when compared to those without a crisis (p < 0.05).Conclusion:
This study found that asthmatic patients had a low prevalence of asthma exacerbation during the coronavirus pandemic period. Patients with acute symptoms may have been underdiagnosed for COVID-19, due to the low demand for emergency care. Previous atopy may act as a protective factor for COVID-19 in asthmatic patients.
corticosteroid; endogenous, compound; interleukin, 13; adult; allergic, asthma; asthenia; atopy; chronic, respiratory, tract, disease; clinical, evaluation; comorbidity; conference, abstract; consultation; controlled, study; coughing; demography; diabetes, mellitus; dyspnea; electronic, medical, record; emergency, care; emotional, stress; female; headache; human; hypertension; major, clinical, study; male; middle, aged; nonhuman; obesity; pandemic; prevalence; prevention; retrospective, study; Severe, acute, respiratory, syndrome, coronavirus, 2; telephone
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Allergy: European Journal of Allergy and Clinical Immunology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS